Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/detail.php on line 234

Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 82

Warning: array_push() expects parameter 1 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 85
Pharmalicensing | Life Science's Global Technology Marketplace
Save this technology
close
Save to Existing Project
Save to a New Project
A Novel Peptide for Treatment of SLE
Yeda R&D Co. Ltd Israel flag Israel
Abstract ID:
A synthetic peptide immunomodulator designed to treat Systemic Lupus Erythematosus (SLE). SLE is a chronic, disabling and potentially life-threatening autoimmune disorder that involves multiple organ systems including the skin, joints, heart, lungs,......
Contact Galit Mazooz, ph.d.
Participants
You
Email me a copy of this message

A synthetic peptide immunomodulator designed to treat Systemic Lupus Erythematosus (SLE).
SLE is a chronic, disabling and potentially life-threatening autoimmune disorder that involves multiple organ systems including the skin, joints, heart, lungs, blood, kidneys and, in the most severe cases, the brain. SLE can occur at any age and in any gender, but afflicts mostly women between the ages of 15 and 50. There is a significant unmet need in the treatment of SLE, as current therapies lack specificity and can often cause considerable adverse side effects. The present invention is a novel drug, designated hCDR1, that specifically targets SLE pathogenesis without causing severe side effects and may therefore constitute a potential alternative for currently used SLE drugs.



Applications




    • Targeted immune-modulating therapy for safer and more specific treatment for SLE patients.





Advantages




    • hCDR1 is designed to target specifically the SLE-associated autoimmune responses without affecting any other functions of the immune system.





    • hCDR1 is associated with moderate side effects when compared with currently used drugs for the treatment of SLE.





    • hCDR1 introduces a ‘gentler’ immune-modulating therapy aimed at the restoration of balance in the patient’s immune networks, rather than completely suppress them as current therapies do.





    • Both phase Ia, Ib & phase II studies showed that once-weekly s.c. injections of hCDR1 to SLE patients were safe and well tolerated.





    • Phase II studies also revealed a clinical effect of hCDR1 (0.5mg) in several clinical parameters.






Technology's Essence


The hallmark of SLE is characterized by an increased production of pathological autoantibodies, directed against patients' own cellular antigens. In the outlined technology, a synthetic peptide was designed based on the complementarily determining region (CDR) 1 of an anti-DNA autoantibody. Treatment with this peptide ameliorated the serological and clinical manifestations of lupus in animal models of SLE. The mechanism of action of hCDR1 involves the upregulation of a subset of regulatory T cells which in turn leads to diminished production of pathogenic cytokines and to upregulation of immunosuppressive cytokines. Moreover, it was shown that hCDR1 is able to downregulate multiple biological pathways, such as apoptosis, cell migration and cell adhesion that play important roles in the pathogenesis of lupus. Taken together, treatment with hCDR1 initiates a cascade of events that culminate in the clinical improvement of SLE.



Licensing Status


 

GO PREMIUM TO GET PATENT INFORMATION
FEATURED
Last Updated May 2016
Technology Type THERAPEUTIC
Phase of Development EARLY STAGE
CORPORATION